Skip to content
Cefotetan
Cefotan (cefotetan) is a small molecule pharmaceutical. Cefotetan was first approved as Cefotan on 1985-12-27. It is used to treat abscess, bacterial infections, bacterial skin diseases, bacteroides infections, and clostridium infections amongst others in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
musculoskeletal diseasesD009140
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
signs and symptoms pathological conditionsD013568
wounds and injuriesD014947
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cefotetan disodium
Tradename
Company
Number
Date
Products
CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINERB. Braun MedicalN-065430 DISCN2007-08-09
2 products, RLD
CEFOTANPAI PharmaN-050588 DISCN1985-12-27
3 products, RLD
CEFOTAN IN PLASTIC CONTAINERPAI PharmaN-050694 DISCN1993-07-30
2 products
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cefotan New Drug Application2018-11-30
cefotetanANDA2020-09-22
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
abscessEFO_0003030D000038—
bacterial infections—D001424A49
bacterial skin diseases—D017192—
bacteroides infectionsEFO_1000832D001442—
clostridium infectionsEFO_1000874D003015A05.2
escherichia coli infectionsEFO_1001318D004927B96.20
fusobacterium infectionsEFO_1000943D005674—
gonorrheaDOID_7551D006069A54
haemophilus infectionsEFO_1001127D006192—
human bites—D001734W50.3
Show 11 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01D: Other beta-lactam antibacterials in atc
— J01DC: Second-generation cephalosporins
— J01DC05: Cefotetan
HCPCS
Code
Description
S0074
Injection, cefotetan disodium, 500 mg
Clinical
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCEFOTETAN
INNcefotetan
Description
Cefotetan is a semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms. It has a role as an antibacterial drug. It is a conjugate acid of a cefotetan(2-).
Classification
Small molecule
Drug classcephalosporins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CO[C@@]1(NC(=O)C2SC(=C(C(N)=O)C(=O)O)S2)C(=O)N2C(C(=O)O)=C(CSc3nnnn3C)CS[C@@H]21
Identifiers
PDB—
CAS-ID69712-56-7
RxCUI—
ChEMBL IDCHEMBL474579
ChEBI ID3499
PubChem CID53025
DrugBankDB01330
UNII ID48SPP0PA9Q (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 1,648 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9 adverse events reported
View more details